Roche, reMYND in neurology deal

Roche (SIX:ROG; OTCQX:RHHBY) and reMYND N.V. (Leuven, Belgium) partnered to develop two reMYND preclinical programs to treat Parkinson's disease (PD) and Alzheimer's disease (AD). The programs consist of small molecules against undisclosed targets that prevent alpha-synuclein ( SNCA) neurotoxicity and microtubule-associated protein tau (MAPT; tau; FTDP-17) neurotoxicity to treat PD and AD, respectively. The deal includes lead compounds ReS9-S for PD and ReS19-T for AD, as well as backup compounds. ...